[{"id":"6c31d924-416a-4fac-90f3-4e9e04970c2d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04708470","created_at":"2021-01-19T20:51:59.772Z","updated_at":"2025-02-25T12:27:53.092Z","phase":"Phase 1/2","brief_title":"A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers","source_id_and_acronym":"NCT04708470","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • CD4","pipe":" | ","alterations":" PD-L1 negative","tags":["PD-L1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jingzhuda (entinostat) • bintrafusp alfa (M7824) • PDS01ADC"],"overall_status":"Recruiting","enrollment":" Enrollment 107","initiation":"Initiation: 10/05/2021","start_date":" 10/05/2021","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2025-02-24"},{"id":"84e74e03-8f34-4176-b63b-03c06eac53aa","acronym":"CodeBreaK 202","url":"https://clinicaltrials.gov/study/NCT05920356","created_at":"2023-06-27T14:08:07.537Z","updated_at":"2025-02-25T13:55:19.667Z","phase":"Phase 3","brief_title":"A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)","source_id_and_acronym":"NCT05920356 - CodeBreaK 202","lead_sponsor":"Amgen","biomarkers":" PD-L1 • KRAS","pipe":" | ","alterations":" PD-L1 expression • PD-L1 negative","tags":["PD-L1 • KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PD-L1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • carboplatin • Lumakras (sotorasib)"],"overall_status":"Recruiting","enrollment":" Enrollment 750","initiation":"Initiation: 11/16/2023","start_date":" 11/16/2023","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2031","study_completion_date":" 06/30/2031","last_update_posted":"2025-02-20"},{"id":"1bb11f50-7b59-4eb4-901f-d7b6ac9b157d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04287868","created_at":"2021-01-18T20:48:45.296Z","updated_at":"2025-02-25T14:07:41.725Z","phase":"Phase 1/2","brief_title":"Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies","source_id_and_acronym":"NCT04287868","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • CDKN2A • CD4","pipe":" | ","alterations":" PD-L1 negative","tags":["PD-L1 • CDKN2A • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bintrafusp alfa (M7824) • Versamune HPV • PDS01ADC"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 06/09/2020","start_date":" 06/09/2020","primary_txt":" Primary completion: 07/26/2022","primary_completion_date":" 07/26/2022","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2025-02-19"},{"id":"3fd4e005-f66e-41a9-982d-62459a2e84ea","acronym":"NCI-2018-01581","url":"https://clinicaltrials.gov/study/NCT03606967","created_at":"2021-01-18T17:43:57.034Z","updated_at":"2025-02-25T16:37:09.345Z","phase":"Phase 2","brief_title":"Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer","source_id_and_acronym":"NCT03606967 - NCI-2018-01581","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • PD-L1 • ER • PGR • CD4","pipe":" | ","alterations":" PD-L1 expression • HER-2 negative • PD-L1 negative","tags":["HER-2 • PD-L1 • ER • PGR • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 negative • PD-L1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Imfinzi (durvalumab) • gemcitabine • albumin-bound paclitaxel • Imjudo (tremelimumab-actl) • Trodelvy (sacituzumab govitecan-hziy) • Hiltonol (poly-ICLC) • liposomal gemcitabine (FF-10832)"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 04/13/2021","start_date":" 04/13/2021","primary_txt":" Primary completion: 11/30/2025","primary_completion_date":" 11/30/2025","study_txt":" Completion: 11/30/2025","study_completion_date":" 11/30/2025","last_update_posted":"2025-02-07"},{"id":"c13367c4-1914-4e69-b5ef-4a4c4565814b","acronym":"DANUBE ","url":"https://clinicaltrials.gov/study/NCT02516241","created_at":"2021-01-17T17:19:50.756Z","updated_at":"2025-02-25T16:36:38.272Z","phase":"Phase 3","brief_title":"Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer","source_id_and_acronym":"NCT02516241 - DANUBE ","lead_sponsor":"AstraZeneca","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 underexpression • PD-L1 negative • PD-L1-L","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 underexpression • PD-L1 negative • PD-L1-L"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • Imfinzi (durvalumab) • gemcitabine • Imjudo (tremelimumab-actl)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1126","initiation":"Initiation: 11/02/2015","start_date":" 11/02/2015","primary_txt":" Primary completion: 01/27/2020","primary_completion_date":" 01/27/2020","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"47a36b91-3872-4bf3-8c5d-910cdf540cd0","acronym":"TUGETHER","url":"https://clinicaltrials.gov/study/NCT04789096","created_at":"2021-03-09T15:52:25.212Z","updated_at":"2025-02-25T16:45:21.897Z","phase":"Phase 2","brief_title":"Tucatinib Together with Pembrolizumab and Trastuzumab","source_id_and_acronym":"NCT04789096 - TUGETHER","lead_sponsor":"Breast Cancer Trials, Australia and New Zealand","biomarkers":" HER-2 • PD-L1","pipe":" | ","alterations":" PD-L1 expression • HER-2 positive • HER-2 amplification • HER-2 expression • PD-L1 negative","tags":["HER-2 • PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 positive • HER-2 amplification • HER-2 expression • PD-L1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Herceptin (trastuzumab) • capecitabine • Tukysa (tucatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 57","initiation":"Initiation: 03/07/2023","start_date":" 03/07/2023","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2025-02-05"},{"id":"1ba644d9-46af-4d81-be0f-6a946f789cac","acronym":"","url":"https://clinicaltrials.gov/study/NCT05539365","created_at":"2022-09-14T18:56:14.616Z","updated_at":"2025-02-25T17:38:04.297Z","phase":"Phase 2","brief_title":"Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer","source_id_and_acronym":"NCT05539365","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression • PD-L1 negative","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PD-L1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • aDC1 vaccine"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 02/01/2025","start_date":" 02/01/2025","primary_txt":" Primary completion: 02/01/2027","primary_completion_date":" 02/01/2027","study_txt":" Completion: 02/01/2027","study_completion_date":" 02/01/2027","last_update_posted":"2025-01-29"},{"id":"3328155d-7553-48a6-b065-e0041a8e5d51","acronym":"","url":"https://clinicaltrials.gov/study/NCT04844073","created_at":"2021-04-14T11:52:51.365Z","updated_at":"2025-02-25T17:37:05.429Z","phase":"Phase 1/2","brief_title":"A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer","source_id_and_acronym":"NCT04844073","lead_sponsor":"Takeda","biomarkers":" PD-L1 • KRAS • MSI","pipe":" | ","alterations":" MSI-H/dMMR • PD-L1 negative","tags":["PD-L1 • KRAS • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • PD-L1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TAK-186"],"overall_status":"Recruiting","enrollment":" Enrollment 258","initiation":"Initiation: 03/08/2021","start_date":" 03/08/2021","primary_txt":" Primary completion: 09/27/2025","primary_completion_date":" 09/27/2025","study_txt":" Completion: 11/01/2026","study_completion_date":" 11/01/2026","last_update_posted":"2025-01-29"},{"id":"d78d7b46-d2cc-485a-8c04-81f9d73189d4","acronym":"KEYNOTE-E28","url":"https://clinicaltrials.gov/study/NCT04429542","created_at":"2021-01-18T21:20:02.191Z","updated_at":"2025-02-25T16:10:23.024Z","phase":"Phase 1","brief_title":"Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors","source_id_and_acronym":"NCT04429542 - KEYNOTE-E28","lead_sponsor":"Bicara Therapeutics","biomarkers":" PD-L1","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • KRAS G12D • EGFR amplification • PD-L1 negative • RAS wild-type • KRAS G12 • KRAS G13 • EGFR negative","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • KRAS G12D • EGFR amplification • PD-L1 negative • RAS wild-type • KRAS G12 • KRAS G13 • EGFR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • ficerafusp alfa (BCA101)"],"overall_status":"Recruiting","enrollment":" Enrollment 292","initiation":"Initiation: 06/01/2020","start_date":" 06/01/2020","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2025-01-27"},{"id":"0983518d-a48f-44db-87f7-0f334b50208a","acronym":"Saci-IO TNBC","url":"https://clinicaltrials.gov/study/NCT04468061","created_at":"2021-01-18T21:28:18.947Z","updated_at":"2025-02-25T16:10:30.435Z","phase":"Phase 2","brief_title":"Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC","source_id_and_acronym":"NCT04468061 - Saci-IO TNBC","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" HER-2 • PD-L1 • ER • PGR","pipe":" | ","alterations":" PD-L1 expression • HER-2 negative • PD-L1 negative","tags":["HER-2 • PD-L1 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 negative • PD-L1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Trodelvy (sacituzumab govitecan-hziy)"],"overall_status":"Recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 07/20/2020","start_date":" 07/20/2020","primary_txt":" Primary completion: 04/01/2026","primary_completion_date":" 04/01/2026","study_txt":" Completion: 04/01/2029","study_completion_date":" 04/01/2029","last_update_posted":"2024-09-19"},{"id":"01bb6da0-1295-4869-97f4-aac2478019c5","acronym":"","url":"https://clinicaltrials.gov/study/NCT04674683","created_at":"2021-01-19T20:45:32.528Z","updated_at":"2025-02-25T14:29:47.853Z","phase":"Phase 3","brief_title":"Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma","source_id_and_acronym":"NCT04674683","lead_sponsor":"HUYABIO International, LLC.","biomarkers":" BRAF","pipe":" | ","alterations":" PD-L1 expression • BRAF mutation • PD-L1 negative","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • BRAF mutation • PD-L1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Epidaza (chidamide)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 450","initiation":"Initiation: 08/12/2021","start_date":" 08/12/2021","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2024-06-24"},{"id":"7eb5032a-f810-48b6-80fe-022a794eb314","acronym":"","url":"https://clinicaltrials.gov/study/NCT05029999","created_at":"2021-09-01T14:53:00.539Z","updated_at":"2024-07-02T16:34:26.023Z","phase":"Phase 1","brief_title":"CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer","source_id_and_acronym":"NCT05029999","lead_sponsor":"University of Texas Southwestern Medical Center","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 negative","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pegylated liposomal doxorubicin • CDX-1140 • Mobista (CDX-301)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 04/20/2022","start_date":" 04/20/2022","primary_txt":" Primary completion: 04/20/2025","primary_completion_date":" 04/20/2025","study_txt":" Completion: 04/20/2025","study_completion_date":" 04/20/2025","last_update_posted":"2024-06-14"},{"id":"5f860286-e6e3-44bc-a0d0-5065d0478838","acronym":"ASCENT-03","url":"https://clinicaltrials.gov/study/NCT05382299","created_at":"2022-05-19T11:56:14.957Z","updated_at":"2024-07-02T16:34:26.679Z","phase":"Phase 3","brief_title":"Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer","source_id_and_acronym":"NCT05382299 - ASCENT-03","lead_sponsor":"Gilead Sciences","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression • PD-L1 negative","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PD-L1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • gemcitabine • albumin-bound paclitaxel • Trodelvy (sacituzumab govitecan-hziy)"],"overall_status":"Recruiting","enrollment":" Enrollment 540","initiation":"Initiation: 07/20/2022","start_date":" 07/20/2022","primary_txt":" Primary completion: 05/01/2027","primary_completion_date":" 05/01/2027","study_txt":" Completion: 05/01/2027","study_completion_date":" 05/01/2027","last_update_posted":"2024-06-12"},{"id":"555f4a0d-f843-45d3-937e-da35717f6f0f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03893955","created_at":"2021-01-18T19:10:50.774Z","updated_at":"2024-07-02T16:34:37.718Z","phase":"Phase 1","brief_title":"A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT03893955","lead_sponsor":"AbbVie","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative • PD-L1 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PD-L1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • albumin-bound paclitaxel • budigalimab (ABBV-181) • giloralimab (ABBV-927) • revdofilimab (ABBV-368)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 05/21/2019","start_date":" 05/21/2019","primary_txt":" Primary completion: 09/29/2024","primary_completion_date":" 09/29/2024","study_txt":" Completion: 09/29/2024","study_completion_date":" 09/29/2024","last_update_posted":"2024-06-06"},{"id":"0922e61e-b9c2-40e5-a29b-5cc52bef01ea","acronym":"NEPTUNE","url":"https://clinicaltrials.gov/study/NCT02542293","created_at":"2021-01-18T12:17:59.454Z","updated_at":"2024-07-02T16:35:00.437Z","phase":"Phase 3","brief_title":"Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)","source_id_and_acronym":"NCT02542293 - NEPTUNE","lead_sponsor":"AstraZeneca","biomarkers":" TMB","pipe":" | ","alterations":" PD-L1 negative","tags":["TMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • Imfinzi (durvalumab) • gemcitabine • paclitaxel • Imjudo (tremelimumab-actl) • pemetrexed"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 953","initiation":"Initiation: 11/03/2015","start_date":" 11/03/2015","primary_txt":" Primary completion: 09/21/2020","primary_completion_date":" 09/21/2020","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-05-29"},{"id":"88c4d979-b2be-4f92-b3cd-f26a056f8d8f","acronym":"eVOLVE-Lung02","url":"https://clinicaltrials.gov/study/NCT05984277","created_at":"2023-08-09T14:09:39.751Z","updated_at":"2024-07-02T16:35:00.226Z","phase":"Phase 3","brief_title":"A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.","source_id_and_acronym":"NCT05984277 - eVOLVE-Lung02","lead_sponsor":"AstraZeneca","biomarkers":" EGFR • PD-L1 • ALK • ROS1","pipe":" | ","alterations":" ALK rearrangement • PD-L1 negative • ROS1 rearrangement","tags":["EGFR • PD-L1 • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK rearrangement • PD-L1 negative • ROS1 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • carboplatin • paclitaxel • pemetrexed • volrustomig (MEDI5752)"],"overall_status":"Recruiting","enrollment":" Enrollment 900","initiation":"Initiation: 10/24/2023","start_date":" 10/24/2023","primary_txt":" Primary completion: 05/30/2028","primary_completion_date":" 05/30/2028","study_txt":" Completion: 05/16/2029","study_completion_date":" 05/16/2029","last_update_posted":"2024-05-29"},{"id":"05863608-f300-43a5-8fe7-d4a2003c3fae","acronym":"mRNA-2752-P101","url":"https://clinicaltrials.gov/study/NCT03739931","created_at":"2021-10-27T19:53:08.482Z","updated_at":"2025-02-25T15:08:05.703Z","phase":"Phase 1","brief_title":"Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies","source_id_and_acronym":"NCT03739931 - mRNA-2752-P101","lead_sponsor":"ModernaTX, Inc.","biomarkers":" PD-L1 • BRAF","pipe":" | ","alterations":" PD-L1 negative • BRAF wild-type","tags":["PD-L1 • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 negative • BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • mRNA-2752"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 134","initiation":"Initiation: 11/27/2018","start_date":" 11/27/2018","primary_txt":" Primary completion: 03/10/2026","primary_completion_date":" 03/10/2026","study_txt":" Completion: 03/10/2026","study_completion_date":" 03/10/2026","last_update_posted":"2024-05-17"},{"id":"a5b3cbee-2080-4b0d-8641-716d3852a42a","acronym":"","url":"https://clinicaltrials.gov/study/NCT06364917","created_at":"2024-04-26T16:52:54.150Z","updated_at":"2024-07-02T16:35:07.307Z","phase":"Phase 2","brief_title":"DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC","source_id_and_acronym":"NCT06364917","lead_sponsor":"University of Alabama at Birmingham","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 negative","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • carboplatin • paclitaxel • pemetrexed"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 10/31/2024","start_date":" 10/31/2024","primary_txt":" Primary completion: 01/30/2027","primary_completion_date":" 01/30/2027","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-04-26"},{"id":"0e1c63e1-f6de-4d37-9ced-a5cce7ed01f4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05318469","created_at":"2022-04-08T21:52:57.367Z","updated_at":"2024-07-02T16:35:12.029Z","phase":"Phase 1/2","brief_title":"Ivermectin and Balstilimab for the Treatment of Metastatic Triple Negative Breast Cancer","source_id_and_acronym":"NCT05318469","lead_sponsor":"Yuan Yuan","biomarkers":" HER-2 • PD-L1 • ER • PGR","pipe":" | ","alterations":" HER-2 negative • PD-L1 negative","tags":["HER-2 • PD-L1 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PD-L1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • balstilimab (AGEN2034)"],"overall_status":"Recruiting","enrollment":" Enrollment 41","initiation":"Initiation: 10/13/2023","start_date":" 10/13/2023","primary_txt":" Primary completion: 10/01/2026","primary_completion_date":" 10/01/2026","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2024-04-02"},{"id":"2efe8f4b-4be7-45bd-b66c-0b8123ceb507","acronym":"","url":"https://clinicaltrials.gov/study/NCT05770531","created_at":"2023-03-15T14:02:35.840Z","updated_at":"2024-07-02T16:35:12.611Z","phase":"Phase 2","brief_title":"Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy","source_id_and_acronym":"NCT05770531","lead_sponsor":"Vanderbilt-Ingram Cancer Center","biomarkers":" HER-2 • PD-L1 • ER • PGR","pipe":" | ","alterations":" HER-2 negative • PD-L1 negative","tags":["HER-2 • PD-L1 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PD-L1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Trodelvy (sacituzumab govitecan-hziy)"],"overall_status":"Suspended","enrollment":" Enrollment 120","initiation":"Initiation: 10/02/2023","start_date":" 10/02/2023","primary_txt":" Primary completion: 10/01/2027","primary_completion_date":" 10/01/2027","study_txt":" Completion: 10/01/2028","study_completion_date":" 10/01/2028","last_update_posted":"2024-03-27"},{"id":"56d3ec14-b4cc-42e0-9846-fa13917833dc","acronym":"TROPION-Breast02","url":"https://clinicaltrials.gov/study/NCT05374512","created_at":"2022-05-16T13:53:41.802Z","updated_at":"2024-07-02T16:35:13.566Z","phase":"Phase 3","brief_title":"A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)","source_id_and_acronym":"NCT05374512 - TROPION-Breast02","lead_sponsor":"AstraZeneca","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" PD-L1 expression • PD-L1 negative","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PD-L1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • capecitabine • albumin-bound paclitaxel • Halaven (eribulin mesylate) • Datroway (datopotamab deruxtecan-dlnk)"],"overall_status":"Recruiting","enrollment":" Enrollment 600","initiation":"Initiation: 05/16/2022","start_date":" 05/16/2022","primary_txt":" Primary completion: 12/03/2025","primary_completion_date":" 12/03/2025","study_txt":" Completion: 12/03/2025","study_completion_date":" 12/03/2025","last_update_posted":"2024-03-21"},{"id":"71d0abaf-a3de-40e4-9de3-0a76efd7b3a2","acronym":"ELEVATE TNBC","url":"https://clinicaltrials.gov/study/NCT04958785","created_at":"2022-04-08T23:52:35.380Z","updated_at":"2024-07-02T16:35:14.392Z","phase":"Phase 2","brief_title":"Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer","source_id_and_acronym":"NCT04958785 - ELEVATE TNBC","lead_sponsor":"Gilead Sciences","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression • PD-L1 negative","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PD-L1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • Trodelvy (sacituzumab govitecan-hziy) • magrolimab (ONO-7913)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 92","initiation":"Initiation: 12/14/2021","start_date":" 12/14/2021","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2024-03-15"},{"id":"cf18a12e-1232-491b-b405-b70c744952f4","acronym":"E7389-J081-114","url":"https://clinicaltrials.gov/study/NCT03207672","created_at":"2021-01-17T17:21:15.414Z","updated_at":"2024-07-02T16:35:16.765Z","phase":"Phase 1","brief_title":"Study of E7389 Liposomal Formulation in Participants With Solid Tumor","source_id_and_acronym":"NCT03207672 - E7389-J081-114","lead_sponsor":"Eisai Co., Ltd.","biomarkers":" HER-2 • PD-L1","pipe":" | ","alterations":" HER-2 negative • PD-L1 negative","tags":["HER-2 • PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PD-L1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Halaven (eribulin mesylate) • eribulin liposomal (E7389-LF)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 08/18/2017","start_date":" 08/18/2017","primary_txt":" Primary completion: 07/19/2018","primary_completion_date":" 07/19/2018","study_txt":" Completion: 08/31/2025","study_completion_date":" 08/31/2025","last_update_posted":"2024-03-01"},{"id":"01c9490b-851c-40e3-bd81-bb560b20b9de","acronym":"","url":"https://clinicaltrials.gov/study/NCT04777084","created_at":"2021-03-02T12:52:16.287Z","updated_at":"2024-07-02T16:35:25.092Z","phase":"Phase 1","brief_title":"The Efficacy and Safety of the Bispecific Anti-PD-1/PD-L1 Antibody IBI318 Combined With Lenvatinib in NSCLC.","source_id_and_acronym":"NCT04777084","lead_sponsor":"Hunan Province Tumor Hospital","biomarkers":" ALK • ROS1","pipe":" | ","alterations":" PD-L1 expression • EGFR T790M • PD-L1 negative • ALK fusion • ROS1 fusion • ALK-ROS1 fusion","tags":["ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • EGFR T790M • PD-L1 negative • ALK fusion • ROS1 fusion • ALK-ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lenvima (lenvatinib) • reozalimab (IBI318)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 08/01/2021","start_date":" 08/01/2021","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 12/25/2025","study_completion_date":" 12/25/2025","last_update_posted":"2023-12-27"}]